Thursday, February 16, 2012

Bio-Path Holdings, Inc. (BPTH) Holds Key to Cancer Drug Delivery

Bio-Path is a biotechnology company that holds a technology with the potential to revolutionize the treatment of cancer and other diseases. That’s because its neutral lipid delivery capability enables the systemic delivery of nucleic acid drugs to diseased cells, and that’s something no other technology can do.

The company was founded based upon technology licensed from The University of Texas M.D. Anderson Cancer Center, technology that Bio-Path intends to turn into real treatments for cancer patients through the application of the necessary capital and expertise. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. A second liposomal antisense drug candidate is ready for clinical evaluation for lymphoma and solid tumors. Yet another candidate is a liposomal siRNA cancer drug, currently in the final pre-clinical development stage.

Bio-Path’s neutral lipid delivery technology allows for the systemic distribution of nucleic acid drugs throughout the human body with simple intravenous transfusion. Their delivery technology applies to both double-stranded (siRNA) and single-stranded nucleic acid drugs. Small interfering RNAs, or siRNAs, are the molecules that mediate RNA interference and interfere with the process of producing proteins inside cells. The siRNA are short double-stranded nucleic acid molecules that can be synthesized chemically and introduced into cells, opening doors for the use of siRNAs as drug candidates to treat major diseases such as cancer. Introduction of a double-stranded nucleic acid molecule specific to a target disease-causing protein conditions cellular machinery to shut-down production of that target protein.

Up to now, the biggest challenge facing successful deployment of siRNA drugs has been the lack of a technology that can deliver the double stranded nucleic acid siRNA molecules to the target diseased cells. Bio-Path’s patented delivery technology solves this problem.

For additional information, visit the company’s website at www.BioPathHoldings.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: